Ebene-23.jpg
Ebene-22.jpg
Ebene-21.jpg
Ebene-43.jpg
Ebene-42.jpg
Ebene-41.jpg
Ebene-23.jpg

Facts and figures


Three publications provide the latest data and statistics on the pharmaceuticals market and healthcare system in Switzerland

SCROLL DOWN

Facts and figures


Three publications provide the latest data and statistics on the pharmaceuticals market and healthcare system in Switzerland

PHARMACEUTICALS MARKET SWITZERLAND:

Now in its 23rd edition, this publication appeared as a purely online version in 2016. It is a collection of data and information on a wide variety of aspects of the pharmaceutical market in Switzerland, including key data from Interpharma companies. All individual graphics are available for download.

The global expenditure of Interpharma member companies in 2015 amounted to almost 90 billion francs, of which around 7 billion was spent in Switzerland. Research and development investments far outweigh pharmaceutical sales in Switzerland. Research-based companies in Switzerland spent about twice as much on R&D as they earned here in sales. In 2015, the pharma market grew by 5.3% compared with the previous year to around 5.4 billion francs. In past years, the market had stagnated. The growth came from new and innovative medicines, especially for those for hepatitis C, which can cure this infectious disease in more than 90% of cases.

This publication is available in French and German.

 

 

 

 


HEALTHCARE SYSTEM SWITZERLAND:

This publication appears once a year with the latest facts and figures on health indicators, healthcare costs and how they are financed in Switzerland. In addition, all individual graphics are online and available for download.

In its 35th edition, this publication includes the following information. For example: in 2013, the increase in healthcare costs at 2.5 percent was less than in the previous year (+4.4%). These costs ran to about 69.2 billion francs in 2013. Inpatient treatment accounted for the largest proportion of healthcare costs at 45.2%. The greatest increase compared with 2012 was seen in the cost for outpatient care, which rose by 6.7%. This accounted for 34.2% of total costs. By contrast, the cost of medicines as a share of the total healthcare cost fell further to a new low of 9.1% (2012: 9.2%).

This publication is available in French and German.

 


SWISS HEALTHCARE AND PHARMACEUTICAL MARKET


This publication is an English “best-of” version of the above two brochures, which is only available online. It shows the structure, links and funding streams of Switzerland’s healthcare system along with the latest statistics on the pharmaceuticals market of Switzerland.

All individual graphs are available for download.

 

Ebene-22.jpg

Allianz q brochure


Quality parameters in the health service – from the individual to the group

Allianz q brochure


Quality parameters in the health service – from the individual to the group

Founded in January 2010, allianz q is an alliance of actors from the healthcare sector whose paramount concern is to ensure that quality is entrenched in the healthcare system and continually improved. Following the annual workshop of allianz q, a brochure is always published in which the topic of the workshop is discussed and . Each brochure is devoted to the topic that is discussed and enlarged upon.

This allianz q workshop was held in June for the sixth year running. This time it was about the different ways of looking at quality in the healthcare system. The individual view of quality and the respective demands on quality can vary widely and depend on the personal situation of the individual concerned. For a patient or doctor the defining quality parameters will differ from those of a scientist engaged in drug research or a representative of a health insurer, for example. In the workshop, the participants attempted to extrapolate individual perceptions to form a group way of looking at the issue and parameters were discussed that are required in order to enhance the quality of treatment (outcome quality).

The publication is available in French and German.

 

Ebene-21.jpg

Animal Welfare Report


Annual report outlines activities and achievements in animal welfare

Animal Welfare Report


Annual report outlines activities and achievements in animal welfare

Annual report on the animal welfare activities of Interpharma companies

Annual report on the animal welfare activities of Interpharma companies

This is the sixth time Switzerland’s research-based pharmaceutical industry has published its annual report based on the Animal Welfare Charter it adopted in 2010. This report includes numerous examples of how Interpharma member companies further improved conditions in animal experiments and the protection of laboratory animals within the meaning of the charter during the year under review.

This year’s report contains numerous examples of projects in the area of the 3Rs (Refine, Reduce, Replace) including the winners of two member companies’ 3Rs awards and a new project for housing rats. The report also provides insights into the procedure involved in Interpharma audits, which were carried out jointly by some member companies at three animal breeders from Europe. The foreword this year is by Dr. Hansuli Huber, managing director of Swiss Animal Protection (SAP). Interpharma has been in dialogue with SAP for five years and discusses current animal welfare issues at regular meetings.

This publication is available in English, French and German.

 

Ebene-43.jpg

Health monitor


Good quality of hospitals should be rewarded

Health monitor


Good quality of hospitals should be rewarded

Most important results of the Health Monitor 2016, gfs.bern, June 2016

Most important results of the Health Monitor 2016, gfs.bern, June 2016

The Health Monitor has been a source of reliable information on the relationship of Swiss voters to the healthcare system in Switzerland since 1997. Every year about 1200 representatively selected voters are polled by the research institute gfs.bern on behalf of Interpharma. To allow comparison of the results from one year to another, most of the questions remain the same over the years.

In 2016, transparency on the quality of hospitals remains an important issue for voters: 82% of respondents would like to know the quality data before opting for treatment in a hospital or clinic, and 75% believe publicly accessible quality data would improve the quality of treatment in hospitals. For the first time, a majority of 62% (+21 percentage points) also take the view that good-quality hospitals should receive financial rewards out of the public purse, while poor-quality ones should be penalized. At the same time, cost awareness has increased compared with the previous year, which has led for example to a more critical view of physician density: 60% see a direct correlation between physician density and rising premiums. The high degree of satisfaction with the Swiss healthcare system is almost unchanged.

This publication is available in French and German.

 

Ebene-42.jpg

Benefits brochure


Information brochure published in collaboration with SwissPedNet

Benefits brochure


Information brochure published in collaboration with SwissPedNet

The benefits brochure this year is a collaborative publication for the first time. Our partner for this brochure on “Research for and with children” is SwissPedNet, the Swiss Network of Paediatric Research Centres.

 

More medicines for children

Many medicines that have only been tested in adults are still being dispensed for children. But the body of a child can react quite differently from that of an adult, and active ingredients may be metabolized faster or more slowly. There is therefore an urgent need for the development of treatments specifically for children and adolescents. An expert explains why more studies are needed to ensure protection of children. Fourteen-year-old Darko tells of his participation in one such study and how he dares to do things today he was afraid to do before.

Milestones in the development of paediatric medicines are also presented and, with reference to diabetes and hormone replacement, gut disorders and cancer, examples are shown of where progress has already been made and where there is need for further research. The brochure is obtainable in French and German and has been displayed in more than 2000 doctors’ practices and distributed to paediatric hospitals since September 2016.

Each brochure examines a particular disorder. Patients and their family members are provided with information on the pathogenesis of the disease, the treatment options and current developments in research.

 

Ebene-41.jpg

Europe Flyer


Pharma and research in Switzerland set great store by a constructive policy on Europe

Europe Flyer


Pharma and research in Switzerland set great store by a constructive policy on Europe

The Swiss pharmaceutical industry is the driver of exports for Switzerland’s economy. Even though the markets of the BRIC countries and the US have grown in the last few years, Europa remains by far the most important destination for the export of pharmaceutical products from Switzerland. If the pharmaceutical industry in Switzerland is to remain healthy and continue with its remarkable contribution to the economy in the future, it is dependent on good political framework conditions. These include the absolutely key issue of reasonable and stable relations with Europe. For this reason, the pharmaceutical industry and research in Switzerland set great store by a constructive policy on Europe. The new brochure explains why good trade relations are important and why specialists from both home and abroad are needed, addresses the importance of the bilateral accords, shows why trade barriers are harmful and explains the relevance of Horizon 2020 for Switzerland as a centre for research.

This publication is available in German and French.